Table 1.
Species | PPARγ related strain characteristics | Diet | Experiment type | Gene manipulation | Pharmacological treatment | Endpoints | Reference | |||
---|---|---|---|---|---|---|---|---|---|---|
Agent | Type | PPARγ | CD36 | NAFLD biomarkers | ||||||
Human | NASH patients | + | + | [15] | ||||||
| ||||||||||
Mouse | Wild type | HFD | + | + | [16] | |||||
Liver PPARγ deficient line | HFD | 0 | 0 | |||||||
Wild type | CD | PPARγ transfected | + | + | + | |||||
Liver PPARγ deficient line | CD | PPARγ transfected | + | + | + | |||||
Mouse | Hepatocytes | PPARγ transfected | + | + | + | |||||
Rosiglitazone | Synthetic agonist | + | ++ | ++ | ||||||
Palmitate | Endogenous metabolite | + | ++ | ++ | ||||||
| ||||||||||
Mouse | Functional PPARγ | HFD | + | + | + | [17] | ||||
PPARγ knockout | HFD | 0/+ | 0/+ | 0/+ | ||||||
Mouse | Functional PPARγ | Tissue slices | Oleic acid | Endogenous agonist | + | |||||
Functional PPARγ | Rosiglitazone | Synthetic agonist | + | |||||||
PPARγ knockout | Oleic acid | Endogenous agonist | 0 | |||||||
PPARγ knockout | Rosiglitazone | Synthetic agonist | 0 | |||||||
Functional PPARγ | Hepatocytes | BADGE | Synthetic antagonist | − | ||||||
Functional PPARγ | Oleic acid + BADGE | Endogenous agonist +Synthetic antagonist | 0/+ | |||||||
| ||||||||||
Mouse | Insulin-resistant mice | CD | + | + | + | [18] | ||||
Control mice | CD | Pioglitazone | Synthetic agonist | 0 | ||||||
Insulin-resistant mice | CD | Pioglitazone | Synthetic agonist | 0 | + | ++ | ||||
| ||||||||||
Mouse | Wild type | HFD-safflower oil | 0/+ | 0 | 0/+ | [19] | ||||
Wild type | HFD-butter | + | + | + | ||||||
Wild type | HFD-safflower oil | PPARγ2 knockdown | + | 0/+ | 0/+ | |||||
Wild type | HFD-butter | PPARγ2 knockdown | + | 0/+ | 0/+ | |||||
Wild type | CD | PPARγ transfected | + | + | + | |||||
| ||||||||||
Mouse | JAK2L-tyrosine kinase deficient | CD | + | ++ | ++ | [20] | ||||
Wild type | CD | GW9662 | Synthetic antagonist | 0 | 0 | 0 | ||||
JAK2L-tyrosine kinase deficient | CD | GW9662 | Synthetic antagonist | + | + | + | ||||
| ||||||||||
Mouse | Liver SMS2-overexpressing transgenic line | CD | + | 0/+ | [21] | |||||
lSMS2-deficient knockout line | CD | − | 0/− | |||||||
Wild type | HFD | 1 | 1 | + | ||||||
Liver SMS2-overexpressing transgenic line | HFD | + | + | ++ | ||||||
lSMS2-deficient knockout line | HFD | − | − | − | ||||||
Liver SMS2-overexpressing transgenic line | HFD | GW9662 | Synthetic antagonist | − | ||||||
Human | Huh7 hepatoma cells | Ceramide | Endogenous suppressor | − | − | |||||
| ||||||||||
Mouse | Wild type | CD | Fbw7 knockdown | + | + | ++ | [22] | |||
Wild type | CD | Fbw7/PPARγ2 double knockdown | 0/− | 0/+ | + | |||||
Wild type | CD | Fbw7 transfected | − | − | 0/− | |||||
Mouse | Wild type | Hepatocytes | Fbw7 knockdown | + | + | + | ||||
| ||||||||||
Mouse | Wild type | HFD | + | + | + | [23] | ||||
Wild type | HFD, liquid, overfeeding | ++ | ++ | ++ | ||||||
| ||||||||||
Mouse | Wild type | HFD | 0/+ | 0/+ | 0/+ | [24] | ||||
Obese, hypercholesterolemic, diabetic foz/foz mice | CD | + | + | 0/+ | ||||||
Obese, hypercholesterolemic, diabetic foz/foz mice | HFD | + | ++ | + |
Legend: Bold: in vitro experiments; CD: control diet, HFD: high-fat diet; endpoints: empty cells: endpoint not determined, +: increase, −: decrease, 0: no effect, 1: controls taken for 100%; 0/+ and 0/− are used in cases where a clear-cut decision about the reported effects could not be done.